Using machine learning to design new drugs for psychiatric disorders
Official title: Machine Learning Phenotypic De Novo Drug Design
Funded at Psychogenics, INC. · NIH-10907841 · Data updated 2026-11-12
This study is working on using smart computer techniques to help create better and safer medications for mental health conditions, so patients can have more effective treatment options that really fit their needs.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Psychogenics, INC. NIH-funded |
| Lab location | 1 site (Paramus, UNITED STATES) |
| Project start | August 15, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $499,946 |
| NIH project number | 5R43MH134716-02 |
| Project ID | NIH-10907841 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with psychiatric disorders such as autism, bipolar disorder, or anxiety.
✕Less likely to help
Patients with psychiatric disorders that do not respond to pharmacological treatments or those who are not diagnosed with any CNS-related conditions may not benefit from this research.
What this research studies
This research focuses on improving drug discovery for psychiatric disorders by utilizing machine learning techniques to design new compounds. It aims to address the high failure rates in developing effective treatments by creating a model that links drug structure to their effects on behavior. By leveraging a unique screening platform and a large database of compounds, the project seeks to explore new chemical spaces that have not been previously targeted. Patients may benefit from the development of more effective and safer medications tailored to their specific conditions.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and safer drugs for psychiatric disorders.
How similar studies have gone: Other research has shown promise in using machine learning for drug discovery, indicating that this approach could lead to significant advancements in treatment options.
Where this research is happening
-
Psychogenics, INC.
Paramus, United States Active
Researchers
- Principal investigator: Brunner, Daniela — Psychogenics, INC.
- Study coordinator: Brunner, Daniela
Related research
Other NIH-funded projects on the same topics.
-
EEG-based drug repurposing for rare CNS diseases
A new approach uses EEG brain signatures to find existing drugs that might help people with rare nervous-system disorders.
-
TAAR1 agonists for stopping cocaine use
A promising drug approach is being tested to help people with cocaine use disorder reduce or stop their cocaine use.
-
Investigating new treatments for pain management.
This study is looking for new ways to help manage pain better, and it could lead to improved treatments for people dealing with chronic pain.
-
Analyzing brain wave patterns to find new uses for existing drugs in rare diseases
This study is looking to find new ways to use existing medications for rare diseases and mental health conditions by analyzing brain wave patterns from animal models, making it easier and cheaper to discover helpful treatments for people like you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.